Ferring Pharmaceuticals concluded a Phase II trial in 2014. The goal of the study was to evaluate the safety and effectiveness of an intranasal oxytocin analogue in treating hyperphagia in children and young adults with Prader-Willi Syndrome. Participants were between the ages of 10-18, in nutritional phase 3, and with a genetic confirmation of PWS.
Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study (APAH)
It is important for those with PWS to incorporate physical activity into their daily lives and increasing physical activity in this population is an area of high interest. This study involves a 24-week home-based physical activity suitable for children and adolescents ages 8-15 with PWS as well as obese children without PWS ages 8-11 years. Researcher will study whether this home based program improves physical activity, motor proficiency, central sensory reception and integration, body composition, and quality of life.
